Sustaining healthy weight loss is about much more than cutting calories or injecting drugs, as many glucagon-like peptide-1 ...

Nia Therapeutics Inc. reported data from an in vivo study of its Smart Neurostimulation System, an AI-based brain-computer ...

The U.K. National Institute for Health and Care Excellence posted a draft update on its recommendations for ovarian cancer ...

Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS ...

Excessive production of pro-inflammatory cytokines or aging-related chronic inflammation disrupts immunity and diminishes the ...

Australia’s Therapeutic Goods Administration posted a proposed rework of the agency’s conformity assessment procedures that ...

Pacific including deals and partnerships, grants, preclinical data and other news in brief: Adlai Nortye, Arbormed Harbour Biomed, Biogen, Hyloris, Juangsu Aosaikang, Samsung,Takeda Pharmaceutical, ...

Innocan Pharma Corp., of Herzliya, Israel, plans to list on the NYSE American exchange on or around Jan. 7, 2026, and is also conducting a concurrent offering of securities subject to market ...

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Researchers at Case Western Reserve University and their collaborators described the use of P7C3-A20, a compound that restores nicotinamide adenine dinucleotide (NAD+) homeostasis, as a potential ...

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG ...

Hyloris Pharmaceuticals SA has entered into a license agreement with Arbormed Co. Ltd. for exclusive rights in Europe and Turkey to Arbormed’s novel injectable product candidate for Wilson’s disease.